GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sailong Pharmaceutical Group Co Ltd (SZSE:002898) » Definitions » Forward PE Ratio

Sailong Pharmaceutical Group Co (SZSE:002898) Forward PE Ratio : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Sailong Pharmaceutical Group Co Forward PE Ratio?

Sailong Pharmaceutical Group Co's Forward PE Ratio for today is 0.00.

Sailong Pharmaceutical Group Co's PE Ratio without NRI for today is 0.00.

Sailong Pharmaceutical Group Co's PE Ratio for today is 194.35.


Sailong Pharmaceutical Group Co Forward PE Ratio Historical Data

The historical data trend for Sailong Pharmaceutical Group Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sailong Pharmaceutical Group Co Forward PE Ratio Chart

Sailong Pharmaceutical Group Co Annual Data
Trend
Forward PE Ratio

Sailong Pharmaceutical Group Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Sailong Pharmaceutical Group Co's Forward PE Ratio

For the Biotechnology subindustry, Sailong Pharmaceutical Group Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sailong Pharmaceutical Group Co's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sailong Pharmaceutical Group Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sailong Pharmaceutical Group Co's Forward PE Ratio falls into.



Sailong Pharmaceutical Group Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Sailong Pharmaceutical Group Co  (SZSE:002898) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Sailong Pharmaceutical Group Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sailong Pharmaceutical Group Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sailong Pharmaceutical Group Co (SZSE:002898) Business Description

Traded in Other Exchanges
N/A
Address
No. 47, Haibin South Road, 2nd Floor, Everbright International Trade Center, Guangdong Province, Zhuhai, CHN, 519015
Zhuhai Sailong Pharmaceutical Co Ltd is the pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.
Executives
Tang Lin Director
Long Zhi Xiang Director
Deng Yong Jun Supervisors
Zhou Bei Supervisors
Li Jian Feng Directors, executives

Sailong Pharmaceutical Group Co (SZSE:002898) Headlines

No Headlines